Adherex Technologies (NASDAQ:FENC) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) Head-To-Head Review

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Insider and Institutional Ownership

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Anebulo Pharmaceuticals has a beta of -1.83, indicating that its stock price is 283% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Anebulo Pharmaceuticals and Adherex Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1	1	0	0	1.50
Adherex Technologies	1	1	4	1	2.71

Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 46.81%. Given Adherex Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Anebulo Pharmaceuticals.

Valuation & Earnings

This table compares Anebulo Pharmaceuticals and Adherex Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48 million	($0.19)	-1.77
Adherex Technologies	$44.64 million	8.20	-$9.74 million	($0.29)	-36.17

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anebulo Pharmaceuticals and Adherex Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Summary

Adherex Technologies beats Anebulo Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.